Number of cases with complications ‐ not reported · children up to the age of 7 at risk of upper respiratory tract infection
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Rate of hospitalisation ‐ not reported · children up to the age of 7 at risk of upper respiratory tract infection
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Relief of pain · children with acute postoperative pain
The review found no eligible studies for this question.
2 findings from 1 review
no estimate extracted
Studies not reported
No studies found
no estimate extracted
Studies not reported
No studies found
Patient‐reported pain intensity or pain relief (VAS, NRS or categorical scale) · children with acute postoperative pain
2 findings from 1 review
Adverse events (reported in the first 7 days after the procedure) · children with acute postoperative pain
Ibuprofen showed no clear difference in adverse events (reported in the first 7 days after the procedure) compared with placebo (low certainty).
1 finding from 1 review
Serious adverse events, defined as any medical event at any dose that results in death, is life‐threatening, requires hospitalisation (or prolongation of existing hospitalisation) or results in permanent damage or disability (FDA 2016) · children with acute postoperative pain
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Death (all causes) · people with diabetes and CKD
Sodium‐glucose co‐transporter protein 2 (SGLT2) inhibitors leads to lower all‐cause death median compared with placebo (high certainty).
3P‐MACE median · people with diabetes and CKD
Sodium‐glucose co‐transporter protein 2 (SGLT2) inhibitors probably leads to lower 3P‐MACE median compared with placebo (moderate certainty).
1 finding from 1 review
4P‐MACE median · people with diabetes and CKD
Sodium‐glucose co‐transporter protein 2 (SGLT2) inhibitors probably leads to lower 4P‐MACE median compared with placebo (moderate certainty).
1 finding from 1 review
Kidney composite outcome median · people with diabetes and CKD
Sodium‐glucose co‐transporter protein 2 (SGLT2) inhibitors leads to lower kidney composite outcome median compared with placebo (high certainty).
1 finding from 1 review
Kidney failure · people with diabetes and CKD
Sodium‐glucose co‐transporter protein 2 (SGLT2) inhibitors leads to lower kidney failure median compared with placebo (high certainty).
1 finding from 1 review
Hypoglycaemia requiring third‐party assistance median · people with diabetes and CKD
Sodium‐glucose co‐transporter protein 2 (SGLT2) inhibitors leads to lower hypoglycaemia requiring third‐party assistance median compared with placebo (high certainty).
1 finding from 1 review
Diabetic ketoacidosis median · people with diabetes and CKD
Sodium‐glucose co‐transporter protein 2 (SGLT2) inhibitors probably leads to higher diabetic ketoacidosis median compared with placebo (moderate certainty).
1 finding from 1 review
Dental caries in children · Children and/or adolescents (<18 years) without background systemic disease
Probiotics probably make little to no difference to the number of dental caries versus control (MD -0.24 carious pieces, 95%CI -0.72 to 0.23; low certainty).
1 finding from 1 review
Caries arrestment at the individual (patient) level · Children and adults with active dental caries (aged 1-50; mostly preschool/school children with primary dentition)
Pooling two trials, SDF markedly increased individual-level caries arrestment versus placebo (OR 18.10; ungraded subgroup).
1 finding from 1 review
Participant satisfaction · People of any age with a confirmed diagnosis, by clinical examination and biopsy, of oral submucous fibrosis (OSF)
The review found no eligible studies for this question.
1 finding from 1 review
Maximal mouth opening (interincisal distance) · People of any age with a confirmed diagnosis, by clinical examination and biopsy, of oral submucous fibrosis (OSF)
1 finding from 1 review
Goel 2015 (3-arm: intralesional betamethasone vs lycopene vs placebo, 90 per arm): appeared to show increased interincisal distance in both intervention groups vs placebo, but only between-group differences with no…
1 study · 180 participants
GRADE not reported
Pain at 72 hours · Adults with symptomatic apical periodontitis (no signs of spreading infection or systemic involvement)
1 finding from 1 review
The median pain at 72 hours in the control group was 0 (range 0 to 10); the median pain at 72 hours in the intervention group was the same (median 0, range 0 to 7). P = 0.116 (Mann-Whitney U).
1 study · 72 participants
Low
Range of mandibular motion · People with temporomandibular disorders (TMD)
Occlusal splint showed no clear difference in range of mandibular motion compared with no treatment or placebo (non-occlusal or transparent-foil placebo…; GRADE not reported.
1 finding from 1 review
Systemic antibiotics without surgical intervention (with or without analgesics) vs Matched placebo without surgical intervention (with or without analgesics)
Outcome not reported · Adults with symptomatic apical periodontitis or acute apical abscess
The review found no eligible studies for this question.
1 finding from 1 review